Recombinant Human Erythropoietin Therapy in Amyotrophic Lateral Sclerosis: Safety and Effectiveness
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 김희태 | - |
dc.date.accessioned | 2021-08-04T02:20:04Z | - |
dc.date.available | 2021-08-04T02:20:04Z | - |
dc.date.issued | 20061116 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/hanyang/handle/2021.sw.hanyang/68536 | - |
dc.description.abstract | Amyotrophic lateral sclerosis (ALS) is a rapidly progressive, fatal neurodegenerative condition characterized by loss of upper and lower motor neurons in the brain and spinal cord. | - |
dc.title | Recombinant Human Erythropoietin Therapy in Amyotrophic Lateral Sclerosis: Safety and Effectiveness | - |
dc.type | Conference | - |
dc.citation.conferenceName | 대한신경과학회 추계학술대회 | - |
dc.citation.conferencePlace | 그랜드힐튼호텔 | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
222, Wangsimni-ro, Seongdong-gu, Seoul, 04763, Korea+82-2-2220-1365
COPYRIGHT © 2021 HANYANG UNIVERSITY.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.